Effect of Renin-Angiotensin System Inhibitor on Residual Glomerular Filtration Rate in Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 6, 2012, Pages 554-559

  Itoh, Yoko ^a   Fujikawa, Tetsuya ^a   Toya, Yoshiyuki ^a   Mitsuhashi, Hiroshi ^a   Kobayashi, Naoyuki ^c   Ohnishi, Toshimasa ^a   Tamura, Kouichi ^a   Hirawa, Nobuhito ^b   Yasuda, Gen ^b   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c Soubudai Nieren Clinic   (Japan)

Author keywords

Hemodialysis; Renin angiotensin system inhibitor; Residual renal function

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; RENIN ANGIOTENSIN SYSTEM INHIBITOR; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; URINE VOLUME; WEIGHT CONTROL; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84870531891     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01087.x     Document Type: Article

References (24)

1. Casas JP, Chua W, Loukogeorgakis S etal. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
2. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. MicroAlbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
4. Liao CT, Chen YM, Shiao CC etal. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009;24:2909-14.
5. Ruggenenti P, Fassi A, Ilieva AP etal. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
6. Bonomini V, Albertazzi A, Vangelista A, Bortolotti GC, Stefoni S, Scolari MP. Residual renal function and effective rehabilitation in chronic dialysis. Nephron 1976;16:89-102.
7. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62.
8. Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int 2000;20:439-44.
9. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001;38:85-90.
10. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT, NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-70.
11. Moist LM, Port FK, Orzol SM etal. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000;11:556-64.
12. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002;62:1046-53.
13. Milutinovic J, Cutler RE, Hoover P, Meijsen B, Scribner BH. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int 1975;8:185-90.
14. van Olden RW, van Acker BA, Koomen GC, Krediet RT, Arisz L. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 1995;10:2274-80.
15. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003;114:588-98.
16. Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J Renin Angiotensin Aldosterone Syst 2004;5:146-51.
17. Maschio G, Alberti D, Janin G etal. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
18. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6.
19. Wei Y, Sowers JR, Nistala R etal. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-46.
20. Lastra G, Habibi J, Whaley-Connell AT etal. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009;150:2561-8.
21. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000;20:429-38.
22. Liao CT, Shiao CC, Huang JW etal. Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int 2008;28:S191-5.
23. Maschio G. Protecting the residual renal function: how do ACE inhibitors and calcium antagonists compare? Nephron 1994;67:257-62.
24. Liu JH, Lin HH, Yang YF etal. Subclinical peripheral artery disease in patients undergoing peritoneal dialysis: risk factors and outcome. Perit Dial Int 2009;29:64-71.